Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test product Clear all
Recruiting Phase 2 Interventional

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

NCT02310867
View directory record Official record
Conditions
Immunosuppression
Interventions
Belatacept, Hand transplant
Drug · Procedure
Lead sponsor
Linda Cendales
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Results available

Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors

NCT00308165
View directory record Official record
Conditions
Brain Neoplasms, Primary Malignant
Interventions
Convection-Enhanced Delivery, Topotecan
Procedure · Drug
Lead sponsor
Columbia University
Other
Eligibility
1 Year and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD170401: Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement

NCT03126357
View directory record Official record
Conditions
Smoking
Interventions
Product A, Product B, Product C, Product D, Product E
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 12, 2026, 2:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone controlled-release test formulation, Immediate-release reference drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Results available

Parrying the Pitfalls of PrEP: Project PEACH

NCT05072093
View directory record Official record
Conditions
HIV, STI
Interventions
PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

NCT05275868
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
MGY825
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

NCT04580368
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
CFTR Modulators
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Coaching for HCV and HIV

NCT04314414
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions
PRC brief motivational interview intervention, Phone contact
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

NCT02962648
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Deficiency Anaemia
Interventions
Iron isomaltoside/ferric derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chula Vista, California • La Mesa, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Assess the Quantitative Dermal Transfer Efficiencies of Solids for Multiple Transfer Pathways

NCT02529748
View directory record Official record
Conditions
Environmental Exposure
Interventions
Participants for Surface Skin Sampling, Elemental metallic lead, Tinopal
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Wise: An Innovative Multi-level Intervention to Reduce Alcohol and Illegal Drug Use

NCT02951455
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Critical Dialogue, Capacity Building Project, Quality of Life Wheel, PF, LC
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older · Male only
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome

NCT00201643
View directory record Official record
Conditions
Preterm Delivery
Interventions
Betamethasone or Dexamethasone (2nd course of ACS), Placebo
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

NCT04337515
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease
Interventions
CliniMacs®
Device
Lead sponsor
Christopher Dvorak
Other
Eligibility
Up to 30 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Induction for Fentanyl Dependent Opioid Users

NCT04794790
View directory record Official record
Conditions
Opioid Dependence Fentanyl
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 12, 2026, 2:53 AM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product

NCT07136766
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Facial Toner, Placebo Toner
Drug · Other
Lead sponsor
Good Molecules, LLC
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 12, 2026, 2:53 AM EDT
Recruiting Phase 1 Interventional

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

NCT06736054
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Copper 61-PSMA PET/CT
Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 12, 2026, 2:53 AM EDT
Active, not recruiting Phase 1 Interventional

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Enfortumab Vedotin, Erdafitinib, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Early Phase 1 Interventional Results available

Sensory and Opioid Mechanisms of Affective Touch

NCT03096353
View directory record Official record
Conditions
Pain, Touch
Interventions
Placebo, Naloxone
Other · Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 12, 2026, 2:53 AM EDT
Terminated Not applicable Interventional

Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease

NCT02924194
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
stimulation ON, stimulation OFF
Device
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

NCT07220551
View directory record Official record
Conditions
Healthy Volunteers
Interventions
UCB0022
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 12, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 12, 2026, 2:53 AM EDT